Analyzing Cascadian Therapeutics (CASC) and Uniqure (QURE)

Cascadian Therapeutics (NASDAQ: CASC) and Uniqure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cascadian Therapeutics and Uniqure, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cascadian Therapeutics 1 2 3 0 2.33
Uniqure 0 2 6 0 2.75

Cascadian Therapeutics presently has a consensus price target of $6.00, indicating a potential downside of 39.82%. Uniqure has a consensus price target of $19.86, indicating a potential upside of 2.36%. Given Uniqure’s stronger consensus rating and higher probable upside, analysts plainly believe Uniqure is more favorable than Cascadian Therapeutics.

Volatility and Risk

Cascadian Therapeutics has a beta of 3.96, indicating that its stock price is 296% more volatile than the S&P 500. Comparatively, Uniqure has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.


This table compares Cascadian Therapeutics and Uniqure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cascadian Therapeutics N/A -41.50% -39.04%
Uniqure -338.39% -170.28% -40.50%

Valuation and Earnings

This table compares Cascadian Therapeutics and Uniqure’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cascadian Therapeutics N/A N/A -$57.70 million ($1.35) -7.39
Uniqure $25.10 million 23.81 -$73.37 million ($2.61) -7.43

Cascadian Therapeutics has higher earnings, but lower revenue than Uniqure. Uniqure is trading at a lower price-to-earnings ratio than Cascadian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

80.4% of Cascadian Therapeutics shares are held by institutional investors. Comparatively, 25.0% of Uniqure shares are held by institutional investors. 1.1% of Cascadian Therapeutics shares are held by company insiders. Comparatively, 0.7% of Uniqure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Cascadian Therapeutics beats Uniqure on 8 of the 12 factors compared between the two stocks.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

About Uniqure

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington’s disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply